This presentation will review developments in Canada and internationally over the past 10 years contributing to an essential expansion of the scientific base supporting optimal therapeutic choices for children from birth to adolescence. Emphasis will be placed on the need for improved clinical investigation approaches with a particular targeting of neonates and patients with rare disorders. The creation of a research environment that will encourage innovation remains of paramount importance and a recent breakthrough development in Europe will be described.